Panmira appoints chief executive
Hari Kumar will oversee inflammation portfolio
Until recently, Kumar was chief business officer of Amira Pharmaceuticals and led the transaction with Bristol-Myers Squibb for the sale of Amira's fibrosis programme.
Panmira was spun out of Amira Pharmaceuticals prior to Amira's acquisition by Bristol-Myers Squibb.
Kumar and his team will oversee Panmira's inflammation portfolio, which features a CRTH2 programme. The leading candidate, AM211, has demonstrated inhibition of eosinophils over 24 hours following oral, once-daily dosing in Phase I studies.
The firm says CRTH2 antagonists show promise for several diseases including eosinophilic esophagitis, eosinophilic asthma, COPD, and atopic dermatitis.